Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03267654|
Recruitment Status : Unknown
Verified July 2020 by Qilu Pharmaceutical Co., Ltd..
Recruitment status was: Recruiting
First Posted : August 30, 2017
Last Update Posted : August 3, 2020
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Non-small-cell Lung Cancer||Drug: gefitinib combined with chemotherapy Drug: gefitinib combined with apatinib Drug: gefitinib single agent||Phase 2|
BIM (bcl-2 interacting mediator of cell death) deletion polymorphism and low EGFR mutation abundance were poor clinical response markers to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC patients who had EGFR mutations.This is a phase II clinical trial to investigate the efficacy of combination treatment for patients harboring above risk factors.
Advanced EGFR mutated NSCLC Patients with Bim deletion or EGFR low mutation abundance were randomized divided into following three treatment groups:
A: gefitinib 250mg Qd combined with doublet chemotherapy: pemetrexed (500mg/m²，day 1 ，intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days.
B: gefitinib 250mg Qd combined with apatinib 250mg/d intravenously per 21 days. C: gefitinib 250mg Qd
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Gefitinib Versus Combination of Gefitinib With Chemotherapy or Anti-angiogenesis as 1st Line Treatment in Advanced NSCLC Patients Detected With Bim Deletion or Low EGFR Activating Mutation Abundance：A Randomized, Multicentre, Phase II Study|
|Actual Study Start Date :||October 12, 2017|
|Estimated Primary Completion Date :||October 20, 2020|
|Estimated Study Completion Date :||December 30, 2021|
Experimental: gefitinib combined with chemotherapy
gefitinib 250mg Qd combined with pemetrexed plus carboplatin: pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days.
Drug: gefitinib combined with chemotherapy
Gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours until disease progression, intolerable toxicity or patient withdraw ICF.
Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days. Every 3 weeks is a chemotherapy cycle, and 4 chemotherapy cycles is maximum limit.
Other Name: yiruike
Experimental: gefitinib combined with apatinib
gefitinib 250mg Qd combined with apatinib 250mg per 21 days
Drug: gefitinib combined with apatinib
gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours.
Apatinib 250mg, p.o., q.d. per 21 days. until disease progression, intolerable toxicity, patient withdraw ICF or death.
Other Name: yiruike
Active Comparator: gefitinib single agent
Advanced NSCLC patients with EGFR activating mutation (L858R, 19Del) received gefitinib 250mg Qd orally until progression, intolerable toxicity or death.
Drug: gefitinib single agent
Patients received Gefitinib 250mg q.d. orally until disease progression, intolerable toxicity or death.
Other Name: yiruike
- Progression free survival [ Time Frame: 8 weeks ]From start of anti-cancer therapy until progression or death
- overall survival [ Time Frame: 36 months ]evaluated in the 36th since treatment begain
- objective response rate [ Time Frame: 8 weeks ]Evaluated the rate of complete response and partial response in the 8 weeks since treatment began
- disease control rate [ Time Frame: 8 weeks ]Evaluated the rate of complete response，partial response and stable disease in the 8 weeks since anti-cancer therapy
- duration of response [ Time Frame: 8 weeks ]interval between the time which complete response or partial response happened and progressive disease or death
- safety evaluation [ Time Frame: 8 weeks ]Safety observation indexes were listed as following: adverse events and serious adverse events (according to CommonTerminology Criteria Adverse Events Version 4.03), physical exam, vital signs(blood pressure, heart rate, respiratory rate,body temperature), weight variation, laboratory examination(hematology, blood biochemistry, urinalysis and so on), electrocardiograph(ECG),ultrasonic cardiogram(UCG), ect.
- compare quality of life [ Time Frame: 24 months ]Quality of Life Questionnaire(including QLQ-C30 and QLQ-LC13) evaluated since treatment began.At the end of the trial, the differences between the two indicators were compared with Mixed-effects model repeated measures (MMRM), where the baseline was scored as a covariant and the treatment group as a fixed variable. In addition, the baseline values of the two scores, the value of each visit, and the change value of the baseline were statistically described.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 75 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Volunteered for attending the study, and signed informed consent form (ICF)to participate in the study.
- Cytologically and Histologically documented, locally advanced or recurrent or metastatic (stage IIIb, IIIc, IV) non-small cell lung cancer patients .
- EGFR mutation (exon 19 deletion or exon 21 L858R) with Bim deletion or low abundance for EGFR mutation.
- Age range: 18 years to 75 years.
- Patients must have measurable lesion according to the RECIST (version 1.1) criteria.
- Life expectancy of ≥ 12 weeks
- ECOG (Eastern Cooperative Oncology Group) performance status of ≤ 1.
- Patients hadn't received past system treatment, including cytotoxic drugs; For patients who have received adjuvant or neoadjuvant chemotherapy appears recurrence or metastasis more than 6 months from accepting the last dose of chemotherapy drugs
Adequate organ function as defined by the following criteria:
- Bone marrow function: absolute neutrophil count ≥ 1,500,000,000/L and platelet count ≥100,000,000,000/L and hemoglobin ≥9g/dL.
- Liver function: Total bilirubin ≤ 1.5 ULN (upper limit of normal). AP (alkaline phosphatase), AST ( aspartate aminotransferase) and ALT (alanine transaminase) ≤ 3 ULN in the absence of liver metastases or up to 5 ULN in case of liver metastases.
- Renal function: creatinine clearance ≥ 60 ml/min. (based on modified Cockcroft-Gault formula).
- INR （international normalized ratio）≤ 1.5, and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) ≤ 1.5 ULN.
- For all females of childbearing potential a negative serum/urine pregnancy test must be obtained within 48 hours before enrollment. Postmenopausal women must have been amenorrhoeic for at least 12 months to be considered of non-childbearing potential.
- Fertile men and women must use effective contraception.
- Histology confirmed for squamous carcinomas, including mixed gland scale cancer, small cell lung cancer.
- Poor controlled hypertension, it means systolic pressure ≥140 mmHg and/or diastolic pressure ≥90 mmHg after drug therapy.
- There are imaging evidence of tumor invading or closing to the pulmonary vessels (e.g., pulmonary artery, superior vena cava).
- Thrombosis in 6 months before enrollment, including pulmonary thrombosis or deep venous thrombosis., or patient had medical evidence or history of thrombosis or bleeding tendency regardless of the severity.
- Patients with medical history of hemoptysis (defined as about 2.5ml bright blood) 2 weeks before the enrollments.
- Proteinuria ≥++, or 24h proteinuria ≥1.0g.
- A uncontrolled clinical infection, activity, including but not limited to acute pneumonia.
- Patients with known liver disease: the hepatitis B virus (HBV) infection and hepatitis b virus DNA (HBV DNA) ≥ 500 copy number or ≥100 IU/ml; or more; or hepatitis C virus (HCV) infection; or liver cirrhosis, etc.
- Patients who are at risk of human immunodeficiency virus (HIV) or syphilis infection.
- Patients who have a difficulty in swallowing or drug absorption.
- There are diseases of alimentary canal such as active duodenal ulcer, the ulcerous colitis, intestinal obstruction or other conditions which can cause gastrointestinal bleeding or perforation in the investigator's opinion; or patient has a history of intestinal perforation, intestinal fistula.
- Evaluation of cardiac function: left ventricular ejection fraction < 50% (echocardiography); Moderate or above disorders of mitral valve and tricuspid shut down;, serious/unstable angina or acute myocardial infarction coronary artery bypass surgery in 6 months before enrollment; patients with class 2 and above cardiac dysfunction according to New York heart association (NYHA) classification
- Stroke and transient ischemic in 12 months before enrollment.
- severe ulcer in the skin wound, trauma and mucosa or fractures have been not fully healed.
- Patients received CYP3A4 strong inhibitor and/or inducer in 2 weeks before enrollment; Patients received P-gp and breast cancer resistance protein (BCRP) substrates drug in 2 weeks before enrollment.
- Patients received other anti-tumor treatment at the same time.
- Patients exist serious psychological or mental abnormalities, so patient compliance is not sufficient.
- Poorly controlled serous cavity effusion, including but not limited to malignant pleural effusion, malignant pericardial effusion and malignant peritoneal effusion.
- Patients have a weight loss (≥10%) within 6 weeks before enrollment.
- The pregnancy of female patients test is positive or lactation women.
- Patients haven't been diagnosed other malignant disease, except the basal cell carcinoma and cervical carcinoma.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03267654
|Contact: Caicun Zhou, MDemail@example.com|
|Shanghai Pulmonary Hospital;||Recruiting|
|Shanghai, Shanghai, China, 200000|
|Contact: Caicun Zhou, MD|
|Principal Investigator:||Caicun Zhou||Shanghai Pulmonary Hospital, Shanghai, China|
|Responsible Party:||Qilu Pharmaceutical Co., Ltd.|
|Other Study ID Numbers:||
|First Posted:||August 30, 2017 Key Record Dates|
|Last Update Posted:||August 3, 2020|
|Last Verified:||July 2020|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Protein Kinase Inhibitors
Molecular Mechanisms of Pharmacological Action